Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global PEGylated Drugs Market Status and Forecast (2016-2027)
  • 1.3.2 Global PEGylated Drugs Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global PEGylated Drugs Supply by Company

• 2.1 Global PEGylated Drugs Sales Volume by Company
• 2.2 Global PEGylated Drugs Sales Value by Company
• 2.3 Global PEGylated Drugs Price by Company
• 2.4 PEGylated Drugs Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional PEGylated Drugs Market Status by Category

• 3.1 PEGylated Drugs Category Introduction
  • 3.1.1 Macromolecular Drugs
  • 3.1.2 Small Molecular Drugs
  • 3.1.3 Nanoparticles
• 3.2 Global PEGylated Drugs Market by Category
  • 3.2.1 Global PEGylated Drugs Sales Volume by Category (2016-2021)
  • 3.2.2 Global PEGylated Drugs Sales Value by Category (2016-2021)
  • 3.2.3 Global PEGylated Drugs Price by Category (2016-2021)
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional PEGylated Drugs Market Status by End User/Segment

• 4.1 PEGylated Drugs Segment by End User/Segment
  • 4.1.1 Cancer
  • 4.1.2 Hepatitis C
  • 4.1.3 Leukemia
  • 4.1.4 Severe Combined Immunodeficiency Disease
  • 4.1.5 Rheumatoid Arthritis
  • 4.1.6 Crohn Disease
  • 4.1.7 Others
• 4.2 Global PEGylated Drugs Market by End User/Segment
  • 4.2.1 Global PEGylated Drugs Sales Volume by End User/Segment (2016-2021)
  • 4.2.2 Global PEGylated Drugs Sales Value by End User/Segment (2016-2021)
  • 4.2.3 Global PEGylated Drugs Price by End User/Segment (2016-2021)
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global PEGylated Drugs Market Status by Region

• 5.1 Global PEGylated Drugs Market by Region
  • 5.1.1 Global PEGylated Drugs Sales Volume by Region
  • 5.1.2 Global PEGylated Drugs Sales Value by Region
• 5.2 North America PEGylated Drugs Market Status
• 5.3 Europe PEGylated Drugs Market Status
• 5.4 Asia Pacific PEGylated Drugs Market Status
• 5.5 Central & South America PEGylated Drugs Market Status
• 5.6 Middle East & Africa PEGylated Drugs Market Status

6 North America PEGylated Drugs Market Status

• 6.1 North America PEGylated Drugs Market by Country
  • 6.1.1 North America PEGylated Drugs Sales Volume by Country (2016-2021)
  • 6.1.2 North America PEGylated Drugs Sales Value by Country (2016-2021)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe PEGylated Drugs Market Status

• 7.1 Europe PEGylated Drugs Market by Country
  • 7.1.1 Europe PEGylated Drugs Sales Volume by Country (2016-2021)
  • 7.1.2 Europe PEGylated Drugs Sales Value by Country (2016-2021)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific PEGylated Drugs Market Status

• 8.1 Asia Pacific PEGylated Drugs Market by Country
  • 8.1.1 Asia Pacific PEGylated Drugs Sales Volume by Country (2016-2021)
  • 8.1.2 Asia Pacific PEGylated Drugs Sales Value by Country (2016-2021)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America PEGylated Drugs Market Status

• 9.1 Central & South America PEGylated Drugs Market by Country
  • 9.1.1 Central & South America PEGylated Drugs Sales Volume by Country (2016-2021)
  • 9.1.2 Central & South America PEGylated Drugs Sales Value by Country (2016-2021)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa PEGylated Drugs Market Status

• 10.1 Middle East & Africa PEGylated Drugs Market by Country
  • 10.1.1 Middle East & Africa PEGylated Drugs Sales Volume by Country (2016-2021)
  • 10.1.2 Middle East & Africa PEGylated Drugs Sales Value by Country (2016-2021)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 PEGylated Drugs Manufacturing Cost Analysis
• 11.5 PEGylated Drugs Sales Channel and Distributors Analysis
  • 11.5.1 PEGylated Drugs Sales Channel
  • 11.5.2 PEGylated Drugs Distributors
• 11.6 PEGylated Drugs Downstream Major Buyers

12 Global PEGylated Drugs Market Forecast by Category and by End User/Segment

• 12.1 Global PEGylated Drugs Sales Volume and Sales Value Forecast (2022-2027)
• 12.2 Global PEGylated Drugs Forecast by Category
  • 12.2.1 Global PEGylated Drugs Sales Volume Forecast by Category
  • 12.2.2 Global PEGylated Drugs Sales Value Forecast by Category
  • 12.2.3 Global PEGylated Drugs Price Forecast by Category
• 12.3 Global PEGylated Drugs Forecast by End User/Segment
  • 12.3.1 Global PEGylated Drugs Sales Volume Forecast by End User/Segment
  • 12.3.2 Global PEGylated Drugs Sales Value Forecast by End User/Segment
  • 12.3.3 Global PEGylated Drugs Price Forecast by End User/Segment

13 Global PEGylated Drugs Market Forecast by Region/Country

• 13.1 Global PEGylated Drugs Market Forecast by Region (2022-2027)
  • 13.1.1 Global PEGylated Drugs Sales Volume Forecast by Region (2022-2027)
  • 13.1.2 Global PEGylated Drugs Sales Value Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Takeda Pharmaceutical Company Limited
  • 14.1.1 Company Information
  • 14.1.2 PEGylated Drugs Product Introduction
  • 14.1.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Servier Pharmaceuticals LLC
  • 14.2.1 Company Information
  • 14.2.2 PEGylated Drugs Product Introduction
  • 14.2.3 Servier Pharmaceuticals LLC PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Sandoz
  • 14.3.1 Company Information
  • 14.3.2 PEGylated Drugs Product Introduction
  • 14.3.3 Sandoz PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Roche
  • 14.4.1 Company Information
  • 14.4.2 PEGylated Drugs Product Introduction
  • 14.4.3 Roche PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Pfizer
  • 14.5.1 Company Information
  • 14.5.2 PEGylated Drugs Product Introduction
  • 14.5.3 Pfizer PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Novo Nordisk
  • 14.6.1 Company Information
  • 14.6.2 PEGylated Drugs Product Introduction
  • 14.6.3 Novo Nordisk PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Mylan
  • 14.7.1 Company Information
  • 14.7.2 PEGylated Drugs Product Introduction
  • 14.7.3 Mylan PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Merck
  • 14.8.1 Company Information
  • 14.8.2 PEGylated Drugs Product Introduction
  • 14.8.3 Merck PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Leadiant Biosciences, Inc.
  • 14.9.1 Company Information
  • 14.9.2 PEGylated Drugs Product Introduction
  • 14.9.3 Leadiant Biosciences, Inc. PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Horizon Therapeutics
  • 14.10.1 Company Information
  • 14.10.2 PEGylated Drugs Product Introduction
  • 14.10.3 Horizon Therapeutics PEGylated Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Enzon
• 14.12 Coherus BioSciences
• 14.13 BioMarin Pharmaceutical Inc
• 14.14 Biogen
• 14.15 Bayer Healthcare
• 14.16 AstraZeneca

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global PEGylated Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global PEGylated Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles

Segmented by End User/Segment
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Takeda Pharmaceutical Company Limited
Servier Pharmaceuticals LLC
Sandoz
Roche
Pfizer
Novo Nordisk
Mylan
Merck
Leadiant Biosciences, Inc.
Horizon Therapeutics
Enzon
Coherus BioSciences
BioMarin Pharmaceutical Inc
Biogen
Bayer Healthcare
AstraZeneca